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Introduction
Activated protein C is a well known anti-inflammatory,
anti-apoptotic, and coagulation modulatory medica-
tion for severe sepsis. However, use of drotrecogin
alfa, a type of recombinant human activated protein
C, is still of major concern in practice because it may
induce serious hemorrhagic events. Although several
contraindications have been listed in the guidelines,
its application before or after invasive procedures in
patients with severe sepsis has not been fully defined.
We report a case of an elderly woman with emphyse-
matous nephritis receiving drotrecogin alfa 24 hours
after percutaneous nephrostomy drainage. She did not
suffer from procedure-related bleeding. It is safe to use
drotrecogin alfa in patients with severe sepsis, even 
in those undergoing post-percutaneous nephrostomy
drainage.
Case Report
An 81-year-old female presented with type 2 diabetes
mellitus. She had been taking metformin 300 mg twice
a day and pioglitazone 15 mg daily for the past 10 years.
She was admitted to our hospital because of right
lower abdominal pain, low urine output, and swollen
legs for 6 days. The pain was dull, intermittent, and
progressively increasing in intensity. There was no refer-
ral pain or any aggravating factors. There was no fever,
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nausea, vomiting, change in bowel habit, urinary fre-
quency or urgency, burning sensation, or vaginal dis-
charge. She had no history of abdominal surgery or
abdominal trauma.
In the emergency department, her temperature was
37.4°C, pulse 82 beats/minute, respiration 20 breaths/
minute, and blood pressure 136/79 mmHg. The phy-
sical examination was normal except for a right cos-
tovertebral knocking tenderness and 2 + leg edema.
Her hematocrit was 35.6%, hemoglobin 11.8 g/dL, white
blood count 14,900 with neutrophils 85%, band forms
0%, creatinine 1.5 mg/dL, and blood urea nitrogen
27 mg/dL.
Plain abdominal radiography revealed paralytic ileus
and stool impaction. An abdominal computed tomog-
raphy scan showed a right renal stone, pyelonephritis
involving the right kidney with gas collection in the
renal pelvis and extension to the perirenal and pararenal
spaces (Figure 1). These findings were compatible with
emphysematous pyelonephritis. We then prescribed 
a parenteral antibiotic, flomoxef, 1 g every 8 hours.
Emergency computed tomography—guided percuta-
neous nephrostomy drainage was performed (Figure 2).
In spite of aggressive medical intervention, her body
temperature increased to 40°C and septic shock occurred
while she was being cared for in the intensive care
unit (ICU).
One day later, disseminated intravascular coagulation
developed with a platelet count drop from 12,100/μL
to 6,500/μL, prothrombin time increased to 18.3 sec-
onds, with activated partial thromboplastin time of
43.5 seconds, fibrin-fibrinogen degradation products
greater than 32 μg/mL, D-dimer 5907 ng/mL, and lac-
tic dehydrogenase 334 μg/mL. We changed the par-
enteral antibiotic to meropenem (1 g every 8 hours).
Activated protein C was then prescribed for 96 hours.
Three days after administration of activated protein C,
follow-up white blood count, diffentnt count, C-reactive
protein, platelet count, prothrombin time, and activated
partial thromboplastin time values all improved. There
were no signs of bleeding, despite the presence of per-
cutaneous nephrostomy drainage. After 3 days she was
transferred to a regular ward and was then discharged
home 15 days after admission.
Discussion
Emphysematous pyelonephritis, first reported in 1898,
is a rare and life-threatening, gas-producing infection
of the renal parenchyma and/or perirenal tissue. This
disease is predominantly seen in women and espe-
cially those with diabetes mellitus1–8. It may present
with fever, chills, abdominal pain, nausea, vomiting
and hematuria. Apart from appropriate use of anti-
biotics, surgical intervention is curative for emphy-
sematous pyelonephritis. Percutaneous nephrostomy
drainage is indicated in mild emphysematous pye-
lonephritis or in patients with contraindication for
nephrectomy4,5,9. In this case, the degree of emphyse-
matous pyelonephritis was not so extensive according
to the location of the gas collection6. However, the
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Figure 1. Renal stone (arrow) at the right ureteropelvic junc-
tion and right hydronephrosis with multifocal air collection
within the renal pelvis.
Figure 2. A 22-gauge, fine metallic needle was used to punc-
ture and opacify the right renal pelvis. Filling defects were
noted in the right renal pelvis representing pelvic stones
and right side percutaneous nephrostomy with drainage
catheter insertion for continuous urine drainage.
patient still developed refractory septic shock and
even underwent percutaneous nephrostomy drainage
instead of nephrectomy.
Protein C synthesis in the liver is reduced during
severe sepsis. It is also degraded by elastase secreted
by either leukocytes or pathogens. The decline of the
concentration of activated protein C results in a state of
hypercoagulation and hyperinflammation. Of these
patients, 20–40% will suffer from organ dysfunction
and death10. The anticoagulatory, anti-inflammatory,
and anti-apoptotic effects of activated protein C could
break the viscous cycle between inflammation and
disseminated intravascular coagulopathy in severe
sepsis11,12.
Activated protein C, an important modulator of
coagulation, is converted from the protein C zymogen
by the thrombin-thrombomodulin complex. It can inac-
tivate coagulation factors Va and VIIIa, which inhibit
thrombin generation. Activated protein C can also be 
a profibrinolytic factor because it promotes fibrinolysis
by inhibiting plasminogen activator inhibitor-110,13.
In addition to its role as an anticoagulant, a number
of anti-inflammatory effects and anti-apoptotic prop-
erties have been described13. It has a role in the inhi-
bition of neutrophil chemotaxis and in maintaining
endothelial integrity after binding to endothelial pro-
tein C receptors. Its cytoprotective effects are mediated
by intracellular signaling, which results in interaction
with an adjacent protease-activated receptor via the
S1P1-, Rac1-, PI3-kinase-, and Akt-dependent sphingo-
sine 1-phosphate pathway10,14,15.
Drotrecogin alfa is recombinant human activated
protein C that has significantly reduced the mortality
in patients with severe sepsis12,16. However, it may
increase the risk of bleeding12,17. The risk-benefit ratio
has to be considered in clinical practice18–20. In elderly
patients with severe sepsis, drotrecogin alfa also in-
creases short-term and long-term survival rates, and
vasopressor-free, ventilator-free, ICU-free and hospital-
free days without increasing the incidence of adverse
events of severe sepsis, including serious hemorrhagic
events21. In previous studies, drotrecogin alfa has been
reported to have been safely applied in several elec-
tive and emergency invasive procedures; however, an
identical case study for percutaneous nephrostomy
drainage is not available12,22. In our case, because of
septic shock and disseminated intravascular coagula-
tion, we used drotrecogin alfa for 96 hours and no
bleeding was noted. Our case could be an example of
the safety of drotrecogin alfa in percutaneous nephros-
tomy drainage in the elderly patient with emphyse-
matous pyelonephritis.
Conclusion
Although drotrecogin alfa may induce serious hemor-
rhagic events, its application before or after invasive
procedures in patients with severe sepsis has not been
fully defined. This case provides useful information 
of an elderly woman with emphysematous nephritis,
a disease which even increases the risk of hematuria,
who received drotrecogin alfa 24 hours after percuta-
neous nephrostomy drainage but did not suffer from
procedure-related bleeding. This encourages us to use
drotrecogin alfa in patients with severe sepsis, even in
those who have undergone post percutaneous nephros-
tomy drainage.
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